Update: Merck’s Ifinatamab Deruxtecan Shows Promise In Phase 2 Lung Cancer Trial
Merck & Co. reports Ifinatamab Deruxtecan shows promising response rates in Phase 2 IDeate-Lung01 trial for extensive-stage small cell lung cancer..
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
